Page 3 - Mark Purcell News Today

A pair of pundits became notably more bullish on the company in the wake of its latest results announcement.

NVO earnings call for the period ending September 30, 2023.

The emergent investment mania around a new family of drugs that appears to offer a miracle cure for obesity has made a couple of already big pharmaceutical companies into supergiants.

NVS earnings call for the period ending September 30, 2023.

Weight-loss drugs could be problematic for casino revenue.

Morgan Stanleys analyst Mark Purcell upgrades the rating on the company from Sell to Neutral. The target price has been raised to CHF 98 from CHF 93.

Just eight names were trading in positive territory on the FTSE 100 on Monday afternoon as investors scaled back their appetite for risk, with the mining stocks, Entain and Burberry bearing the brunt of the selling pressure.

Ozempic commercials are, at this point, ubiquitous; it represents confirmation that weight loss drugs are big in the pharmaceuticals industry.

THIS is a roundup of this week’s criminal court and inquest stories that we have covered over the last week.

KEVIN EGAN looks at the strengths and weaknesses of the teams that will be competing in this year’s Hodson Bay Hotel Senior Football Championship…